Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ABT-122 in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate
2014-003558-15Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of remtolumab in psoriatic arthritis (PsA) (3 arms), sponsored by AbbVie Inc. Primary endpoint: ACR20 response at Week 12 (ABT-122 vs placebo). Started Mar 2015; status: completed.
02
Drugs
remtolumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2014-003558-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003558-15.